当前位置: 首页 >> 检索结果
261. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial.
作者: Arie Levine.;Eytan Wine.;Amit Assa.;Rotem Sigall Boneh.;Ron Shaoul.;Michal Kori.;Shlomi Cohen.;Sarit Peleg.;Hussein Shamaly.;Avi On.;Peri Millman.;Lee Abramas.;Tomer Ziv-Baran.;Shannan Grant.;Guila Abitbol.;Katherine A Dunn.;Joseph P Bielawski.;Johan Van Limbergen.
来源: Gastroenterology. 2019年157卷2期440-450.e8页
Exclusive enteral nutrition (EEN) is recommended for children with mild to moderate Crohn's disease (CD), but implementation is challenging. We compared EEN with the CD exclusion diet (CDED), a whole-food diet coupled with partial enteral nutrition (PEN), designed to reduce exposure to dietary components that have adverse effects on the microbiome and intestinal barrier.
262. Efficacy of Prophylactic Hemoclips in Prevention of Delayed Post-Polypectomy Bleeding in Patients With Large Colonic Polyps.
作者: Linda A Feagins.;Andrew D Smith.;Daniel Kim.;Akeel Halai.;Suneetha Duttala.;Benjamin Chebaa.;Tisha Lunsford.;John Vizuete.;Miriam Mara.;Ranjan Mascarenhas.;Rabia Meghani.;Leon Kundrotas.;Kerry B Dunbar.;Daisha J Cipher.;William V Harford.;Stuart J Spechler.
来源: Gastroenterology. 2019年157卷4期967-976.e1页
The efficacy of prophylactic placement of hemoclips to prevent delayed bleeding after removal of large colonic polyps has not been established. We conducted a randomized equivalence study to determine whether prophylactic placement of hemoclips affects incidence of delayed post-polypectomy bleeding (PPB).
263. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
作者: Paul Moayyedi.;John W Eikelboom.;Jackie Bosch.;Stuart J Connolly.;Leanne Dyal.;Olga Shestakovska.;Darryl Leong.;Sonia S Anand.;Stefan Störk.;Kelley R H Branch.;Deepak L Bhatt.;Peter B Verhamme.;Martin O'Donnell.;Aldo P Maggioni.;Eva M Lonn.;Leopoldo S Piegas.;Georg Ertl.;Matyas Keltai.;Nancy Cook Bruns.;Eva Muehlhofer.;Gilles R Dagenais.;Jae-Hyung Kim.;Masatsugu Hori.;P Gabriel Steg.;Robert G Hart.;Rafael Diaz.;Marco Alings.;Petr Widimsky.;Alvaro Avezum.;Jeffrey Probstfield.;Jun Zhu.;Yan Liang.;Patricio Lopez-Jaramillo.;Ajay K Kakkar.;Alexander N Parkhomenko.;Lars Ryden.;Nana Pogosova.;Antonio L Dans.;Fernando Lanas.;Patrick J Commerford.;Christian Torp-Pedersen.;Tomek J Guzik.;Dragos Vinereanu.;Andrew M Tonkin.;Basil S Lewis.;Camilo Felix.;Khalid Yusoff.;Kaj P Metsarinne.;Keith A A Fox.;Salim Yusuf.; .
来源: Gastroenterology. 2019年157卷3期682-691.e2页
Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies. We aimed to confirm these findings in an adequately powered randomized trial.
264. Novel 1 L polyethylene glycol-based bowel preparation (NER1006): proof of concept assessment versus standard 2 L polyethylene glycol with ascorbate - a randomized, parallel group, phase 2, colonoscopist-blinded trial.
作者: Lucy B Clayton.;Bola Tayo.;Marc Halphen.;Rüdiger Kornberger.
来源: BMC Gastroenterol. 2019年19卷1期79页
Colonoscopy requires colon cleansing. For this, many polyethylene glycol (PEG)-based preparations still require a high preparation-volume intake. Using an increased osmotic load with ascorbate (Asc), five new low-volume PEG-based bowel preparations (LVPEG) were tested for clinical proof of concept.
266. Bifidobacteriumbreve Bif195 Protects Against Small-Intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers.
作者: Brynjulf Mortensen.;Clodagh Murphy.;John O'Grady.;Mary Lucey.;Gafer Elsafi.;Lillian Barry.;Vibeke Westphal.;Anja Wellejus.;Oksana Lukjancenko.;Aron C Eklund.;Henrik Bjørn Nielsen.;Adam Baker.;Anders Damholt.;Johan E T van Hylckama Vlieg.;Fergus Shanahan.;Martin Buckley.
来源: Gastroenterology. 2019年157卷3期637-646.e4页
Enteropathy and small-intestinal ulcers are common adverse effects of nonsteroidal anti-inflammatory drugs such as acetylsalicylic acid (ASA). Safe, cytoprotective strategies are needed to reduce this risk. Specific bifidobacteria might have cytoprotective activities, but little is known about these effects in humans. We used serial video capsule endoscopy (VCE) to assess the efficacy of a specific Bifidobacterium strain in healthy volunteers exposed to ASA.
267. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
作者: Paul Moayyedi.;John W Eikelboom.;Jackie Bosch.;Stuart J Connolly.;Leanne Dyal.;Olga Shestakovska.;Darryl Leong.;Sonia S Anand.;Stefan Störk.;Kelly R H Branch.;Deepak L Bhatt.;Peter B Verhamme.;Martin O'Donnell.;Aldo P Maggioni.;Eva M Lonn.;Leopoldo S Piegas.;Georg Ertl.;Matyas Keltai.;Nancy Cook Bruns.;Eva Muehlhofer.;Gilles R Dagenais.;Jae-Hyung Kim.;Masatsugu Hori.;P Gabriel Steg.;Robert G Hart.;Rafael Diaz.;Marco Alings.;Petr Widimsky.;Alvaro Avezum.;Jeffrey Probstfield.;Jun Zhu.;Yan Liang.;Patricio Lopez-Jaramillo.;Ajay Kakkar.;Alexander N Parkhomenko.;Lars Ryden.;Nana Pogosova.;Antonio Dans.;Fernando Lanas.;Patrick J Commerford.;Christian Torp-Pedersen.;Tomek Guzik.;Dragos Vinereanu.;Andrew M Tonkin.;Basil S Lewis.;Camilo Felix.;Khalid Yusoff.;Kaj Metsarinne.;Keith A A Fox.;Salim Yusuf.; .
来源: Gastroenterology. 2019年157卷2期403-412.e5页
Antiplatelets and anticoagulants are associated with increased upper gastrointestinal bleeding. We evaluated whether proton pump inhibitor therapy could reduce this risk.
268. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.
作者: Jian Sun.;Huiguo Ding.;Guofeng Chen.;Guiqiang Wang.;Lai Wei.;Jiming Zhang.;Qing Xie.;Mobin Wan.;Hong Tang.;Shijun Chen.;Zhiliang Gao.;Yuming Wang.;Dazhi Zhang.;Wenxiang Huang.;Jifang Sheng.;Qin Ning.;Dongliang Yang.;Jian Lu.;Chen Pan.;Yuxiu Yang.;Jue Wang.;Chuanzhen Sun.;Qixin Wang.;Jinlin Hou.
来源: BMC Gastroenterol. 2019年19卷1期65页
Pegylated interferon (PEG-IFN) alfa-2b is recommended for chronic hepatitis B (CHB). We aimed to investigate the sustainability of off-treatment responses among Chinese HBeAg-positive CHB patients treated with PEG-IFN alfa-2b from a randomized trial.
269. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
作者: Rene M M van Aerts.;Wietske Kievit.;Hedwig M A D'Agnolo.;Charles J Blijdorp.;Niek F Casteleijn.;Shosha E I Dekker.;Johan W de Fijter.;Maatje van Gastel.;Tom J Gevers.;Liyanne F M van de Laarschot.;Marten A Lantinga.;Monique Losekoot.;Esther Meijer.;A Lianne Messchendorp.;Myrte K Neijenhuis.;Michelle J Pena.;Dorien J M Peters.;Mahdi Salih.;Darius Soonawala.;Edwin M Spithoven.;Folkert W Visser.;Jack F Wetzels.;Robert Zietse.;Ron T Gansevoort.;Joost P H Drenth.; .
来源: Gastroenterology. 2019年157卷2期481-491.e7页
Polycystic liver disease is the most common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). There is need for robust long-term evidence for the volume-reducing effect of somatostatin analogues. We made use of data from an open-label, randomized trial to determine the effects of lanreotide on height-adjusted liver volume (hTLV) and combined height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD.
270. Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma.
作者: Keiko Minashi.;Keiji Nihei.;Junki Mizusawa.;Kohei Takizawa.;Tomonori Yano.;Yasumasa Ezoe.;Tomohiro Tsuchida.;Hiroyuki Ono.;Toshiro Iizuka.;Noboru Hanaoka.;Ichiro Oda.;Yoshinori Morita.;Masahiro Tajika.;Junko Fujiwara.;Yoshinobu Yamamoto.;Chikatoshi Katada.;Shinichiro Hori.;Hisashi Doyama.;Tsuneo Oyama.;Hiroko Nebiki.;Kenji Amagai.;Yutaro Kubota.;Ken Nishimura.;Nozomu Kobayashi.;Takuto Suzuki.;Kingo Hirasawa.;Toshihisa Takeuchi.;Haruhiko Fukuda.;Manabu Muto.
来源: Gastroenterology. 2019年157卷2期382-390.e3页
Esophagectomy is the standard treatment for stage I esophageal squamous cell carcinoma (ESCC). We conducted a single-arm prospective study to confirm the efficacy and safety of selective chemoradiotherapy (CRT) based on findings from endoscopic resection (ER).
271. Comparison of Underwater vs Conventional Endoscopic Mucosal Resection of Intermediate-Size Colorectal Polyps.
作者: Takeshi Yamashina.;Noriya Uedo.;Tomofumi Akasaka.;Taro Iwatsubo.;Yasuki Nakatani.;Takuji Akamatsu.;Takuji Kawamura.;Yoji Takeuchi.;Shigehiko Fujii.;Toshihiro Kusaka.;Toshio Shimokawa.
来源: Gastroenterology. 2019年157卷2期451-461.e2页
Endoscopic mucosal resection (EMR) with submucosal injection is an established method for removing colorectal polyps, although the en bloc resection rate decreases when polyp size exceeds 10 mm. Piecemeal resection increases local recurrence. Underwater EMR (UEMR) is an effective technique for removal of sessile colorectal polyps and we investigated whether it is superior to conventional EMR (CEMR).
272. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
作者: Carolina Boni.;Harry L A Janssen.;Marzia Rossi.;Seung Kew Yoon.;Andrea Vecchi.;Valeria Barili.;Eric M Yoshida.;Huy Trinh.;Timothy C Rodell.;Diletta Laccabue.;Arianna Alfieri.;Federica Brillo.;Paola Fisicaro.;Greta Acerbi.;Giuseppe Pedrazzi.;Pietro Andreone.;Carmela Cursaro.;Marzia Margotti.;Rosanna Santoro.;Valeria Piazzolla.;Maurizia R Brunetto.;Barbara Coco.;Daniela Cavallone.;Yang Zhao.;Adarsh Joshi.;Jacky Woo.;Audrey H Lau.;Anuj Gaggar.;G Mani Subramanian.;Benedetta Massetto.;Scott Fung.;Sang Hoon Ahn.;Xiaoli Ma.;Alessandra Mangia.;Carlo Ferrari.
来源: Gastroenterology. 2019年157卷1期227-241.e7页
One strategy to treat chronic hepatitis B virus (HBV) infection could be to increase the functions of virus-specific T cells. We performed a multicenter phase 2 study to evaluate the safety and efficacy of GS-4774, a yeast-based therapeutic vaccine engineered to express HBV antigens, given with tenofovir disoproxil fumarate (TDF) to untreated patients with chronic HBV infection.
273. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
作者: Alfredo J Lucendo.;Stephan Miehlke.;Christoph Schlag.;Michael Vieth.;Ulrike von Arnim.;Javier Molina-Infante.;Dirk Hartmann.;Albert Jan Bredenoord.;Constanza Ciriza de Los Rios.;Stefan Schubert.;Stefan Brückner.;Ahmed Madisch.;Jamal Hayat.;Jan Tack.;Stephen Attwood.;Ralph Mueller.;Roland Greinwald.;Alain Schoepfer.;Alex Straumann.; .
来源: Gastroenterology. 2019年157卷1期74-86.e15页
Swallowed topical-acting corticosteroids are recommended as first-line therapy for eosinophilic esophagitis (EoE). Asthma medications not optimized for esophageal delivery are sometimes effective, although given off-label. We performed a randomized, placebo-controlled trial to assess the effectiveness and tolerability of a budesonide orodispersible tablet (BOT), which allows the drug to be delivered to the esophagus in adults with active EoE.
274. Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis.
作者: Javier Fernández.;Joan Clària.;Alex Amorós.;Ferrán Aguilar.;Miriam Castro.;Mireia Casulleras.;Juan Acevedo.;Marta Duran-Güell.;Laura Nuñez.;Montserrat Costa.;Mireia Torres.;Raquel Horrillo.;Luis Ruiz-Del-Árbol.;Cándido Villanueva.;Verónica Prado.;Mireya Arteaga.;Jonel Trebicka.;Paolo Angeli.;Manuela Merli.;Carlo Alessandria.;Niels Kristian Aagaard.;German Soriano.;François Durand.;Alexander Gerbes.;Thierry Gustot.;Tania M Welzel.;Francesco Salerno.;Rafael Bañares.;Victor Vargas.;Agustin Albillos.;Aníbal Silva.;Manuel Morales-Ruiz.;Juan Carlos García-Pagán.;Marco Pavesi.;Rajiv Jalan.;Mauro Bernardi.;Richard Moreau.;Antonio Páez.;Vicente Arroyo.
来源: Gastroenterology. 2019年157卷1期149-162页
We investigated the effect of albumin treatment (20% solution) on hypoalbuminemia, cardiocirculatory dysfunction, portal hypertension, and systemic inflammation in patients with decompensated cirrhosis with and without bacterial infections.
275. Clip Closure Prevents Bleeding After Endoscopic Resection of Large Colon Polyps in a Randomized Trial.
作者: Heiko Pohl.;Ian S Grimm.;Matthew T Moyer.;Muhammad K Hasan.;Douglas Pleskow.;B Joseph Elmunzer.;Mouen A Khashab.;Omid Sanaei.;Firas H Al-Kawas.;Stuart R Gordon.;Abraham Mathew.;John M Levenick.;Harry R Aslanian.;Fadi Antaki.;Daniel von Renteln.;Seth D Crockett.;Amit Rastogi.;Jeffrey A Gill.;Ryan J Law.;Pooja A Elias.;Maria Pellise.;Michael B Wallace.;Todd A Mackenzie.;Douglas K Rex.
来源: Gastroenterology. 2019年157卷4期977-984.e3页
Bleeding is the most common severe complication after endoscopic mucosal resection of large colon polyps and is associated with significant morbidity and cost. We examined whether prophylactic closure of the mucosal defect with hemoclips after polyp resection reduces the risk of bleeding.
276. A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn's Disease Flares.
作者: Lindsey Albenberg.;Colleen M Brensinger.;Qufei Wu.;Erin Gilroy.;Michael D Kappelman.;Robert S Sandler.;James D Lewis.
来源: Gastroenterology. 2019年157卷1期128-136.e5页
Diet may be an important factor in the progression of Crohn's disease (CD). We performed a randomized controlled trial to determine whether reduced consumption of red and processed meats decreases the risk of symptomatic relapse of CD, analyzing results from the Food and Crohn's Disease Exacerbation Study (FACES) trial.
277. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
作者: Evan S Dellon.;John T Woosley.;Ashley Arrington.;Sarah J McGee.;Jacquelyn Covington.;Susan E Moist.;Jessica H Gebhart.;Alexandra E Tylicki.;Shiyan O Shoyoye.;Christopher F Martin.;Joseph A Galanko.;John A Baron.;Nicholas J Shaheen.
来源: Gastroenterology. 2019年157卷1期65-73.e5页
Topical steroid treatments for eosinophilic esophagitis (EoE) include swallowed fluticasone from a multi-dose inhaler (MDI) or oral viscous budesonide (OVB) slurry, but the 2 have never been compared. We assessed whether OVB was more effective than MDI for initial treatment of patients with EoE.
278. Efficacy of Injection of Freshly Collected Autologous Adipose Tissue Into Perianal Fistulas in Patients With Crohn's Disease.
作者: Anders Dige.;Helene Tarri Hougaard.;Jørgen Agnholt.;Bodil Ginnerup Pedersen.;Michaela Tencerova.;Moustapha Kassem.;Klaus Krogh.;Lilli Lundby.
来源: Gastroenterology. 2019年156卷8期2208-2216.e1页
Perianal fistulas are common in patients with Crohn's disease (CD). Injections of cultured autologous and allogeneic adipose tissue-derived stem cells have been shown to heal CD-associated fistulas. Unfortunately, this treatment is time consuming and expensive. We investigated the effects of injecting freshly collected autologous adipose tissue into perianal fistulas in patients with CD.
279. Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography.
作者: Takeshi Tomoda.;Hironari Kato.;Toru Ueki.;Yutaka Akimoto.;Hidenori Hata.;Masakuni Fujii.;Ryo Harada.;Tsuneyoshi Ogawa.;Masaki Wato.;Masahiro Takatani.;Minoru Matsubara.;Yoshinari Kawai.;Hiroyuki Okada.
来源: Gastroenterology. 2019年156卷6期1753-1760.e1页
Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP). Rectal administration of nonsteroidal anti-inflammatory drugs (NSAIDs) decreases the incidence of post-ERCP pancreatitis (PEP). Little is known about the combined effects of sublingual nitrate and NSAIDs. We performed a randomized trial to assess whether the combination of NSAIDs and sublingual nitrate is more effective than NSAIDs alone in preventing PEP.
280. Moderate-intensity aerobic and resistance exercise is safe and favorably influences body composition in patients with quiescent Inflammatory Bowel Disease: a randomized controlled cross-over trial.
作者: Owen Cronin.;Wiley Barton.;Carthage Moran.;Donal Sheehan.;Ronan Whiston.;Helena Nugent.;Yvonne McCarthy.;Catherine B Molloy.;Orla O'Sullivan.;Paul D Cotter.;Michael G Molloy.;Fergus Shanahan.
来源: BMC Gastroenterol. 2019年19卷1期29页
Overweight and metabolic problems now add to the burden of illness in patients with Inflammatory Bowel Disease. We aimed to determine if a program of aerobic and resistance exercise could safely achieve body composition changes in patients with Inflammatory Bowel Disease.
|